Control of retinal cell fate specification by the miR9-2 disease gene locus
- Institution
- Seattle Children's Hospital, WA
- Principal investigator
- Katelyn Ning Lulu Callies
- Funding
- $45K
- Duration
- 2024–2027
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY The development of a functional central nervous system is dependent upon the proper specification of distinct cell fates by multipotent progenitor cells. While the role of protein-coding genes in this process is well studied, there is a pressing need to understand how non-coding elements, such as microRNAs (miRNAs) and enhancers, contribute to cell fate decisions as a growing number of studies implicate non-coding genomic elements in disease. The long term goal of this project is to elucidate how the microRNA, miR9-2 regulates the timing of cell fate specification during retinal development. miR9-2, along with its distal enhancer, has been linked to retinal disease and associated phenotypes, and disruption of miR9-2, through deletion of its enhancer, can delay the emergence of late-born cell classes. Therefore, the hypothesis of this proposal is that miR9-2, in coordination with its enhancer, regulates specific target transcripts in progenitor cells to control the timing of neurogenesis during retinal development. Here, using in vivo mouse models, single-cell sequencing, and machine-learning directed enhancer bashing approaches, this proposal will dissect the functional role of miR9-2 and its enhancer to understand the regulatory role they play in proper specification of retinal cell classes. The proposed research is significant, because it will provide a comprehensive understanding of the enhancer-miR9-2 regulatory unit and the gene networks, cell classes, and retinal structures under its control. This will further provide an opportunity to model the mechanisms of action by which non-coding elements influence the development and diseases of the central nervous system and may lead to gene targets and pathways with therapeutic potential.
LOADING MOONBASE SCORE
Questions for Seattle Children's Hospital
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Seattle Children's Hospital48
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).
Christopher Hooper Goss · $739K · 2020–2027
- NIH · Seattle Children's HospitalReviewed
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
Molly Adrian · $1.0M · 2021–2027
- NIH · Seattle Children's HospitalNot yet scored
Invent@SC Clinical Pharmacology of Biotherapeutics
Franck K Kalume · $166K · 2025–2030